Axon Partners Group, a leading technology investment and consulting firm, announces the appointment of Chema Guillamot as Senior Manager within the Sustainability and Energy Transition Investment Team.

Guillamot brings extensive experience in energy transition and sustainable investments. He previously led investment initiatives at Kira Ventures, where he focused on early stage startups shaping the future of clean energy. Before that, he was part of Alantra’s Energy Transition team, contributing to strategic transactions in the sector. His roles at Enagás and BNP Paribas gave him in-depth knowledge of infrastructure finance, carbon markets, and sustainable investment strategies.

At Axon, Guillamot will play a key role in identifying and supporting pioneering companies advancing the energy transition, further reinforcing the firm’s commitment to sustainability and innovation.

This appointment strengthens Axon’s capabilities in the sustainability sector, a strategic area for the firm. Chema’s expertise will be instrumental in expanding the company’s presence in sustainable investments, aligning with the organization’s strategic objectives.

Download Press Release

SANTA BARBARA, CA—QAD, a leading provider of cloud-based solutions for manufacturers and supply chains, today announced the appointment of Sanjay Brahmawar, formerly CEO of Software AG, as its new Chief Executive Officer. Sanjay begins in his new role on March 17, succeeding Anton Chilton, who is stepping back from his role after more than 20 years of service.

During his time at Software AG, Sanjay drove a transformation program that saw the business evolve into a modern growth company. His focus on clarity of vision and high-quality execution saw the Company enhance its reputation for product leadership, build a leading customer-centric go-to-market organization, and sharpen its offering through high-quality M&A.

Prior to Software AG, Sanjay held several senior positions at IBM, including managing global revenue for Watson IoT. His strong track record of relevant experience also includes roles at PwC, FedEx, DSM and Honda.

He begins his time at QAD with a clear mission to drive growth through product innovation and customer success.

Charles Goodman, Chairman of the QAD Board of Directors and Thoma Bravo Operating Partner, expressed strong support for the new leadership: “Sanjay joins QAD at a pivotal time in its journey. His expertise in innovation and his strong sense of customer needs make him the perfect choice to lead us forward.”

Sanjay Brahmawar, incoming CEO of QAD, added: “I’m incredibly excited to lead QAD into this next phase of growth and success. I want our customers to know I value their trust and am 100% committed to their success. And I want our people to know that we’re going to work hard together to build a QAD that plays to win.”

Anton Chilton will be available through May 2025 to ensure a seamless transition. Under his leadership, QAD enhanced its core capabilities through strategic acquisitions, including Redzone Connected Workforce and LiveJourney Process Intelligence. These additions have bolstered the optimization of People, Process, and Systems, empowering frontline workers with real-time collaboration tools and providing advanced process mining to streamline operations.

About QAD
QAD Inc. is a leading provider of next-generation manufacturing and supply chain solutions in the cloud. A Thoma Bravo portfolio company since its acquisition in 2021, QAD empowers global manufacturers and supply chains facing ever-increasing disruption. QAD solutions help customers rapidly adapt to change and innovate for competitive advantage. For more information, visit www.qad.com.

Read the release on Business Wire here.

We are seeking an Investment Intern for the autumn of 2025

Are You Ready to Make an Impact?
Are you a highly motivated and talented individual with a passion for supporting companies in achieving their full potential? We are currently seeking a full-time Investment Intern to join us for the autumn of 2025. This position offers a unique opportunity to gain valuable experience in the field of investment and become an integral member of our team.

What You’ll Do
As an Investment Intern, you will:

• Analyse potential platform investments
• Prepare financial models and valuation materials
• Evaluate add-on opportunities
• Support the implementation of strategic initiatives within our portfolio companies

What We’re Looking For
We value collaborative team players who can work effectively within a group. However, you will also be entrusted with substantial responsibility, making attention to detail and a proactive approach essential. In addition, the ideal candidate should demonstrate and fulfill the following qualities and criteria:

• Prior work experience in investment banking, management consulting, or within another investment firm is preferred
• High proficiency in Microsoft Office, particularly Excel
• Fluency in both Swedish and English
• Currently in their third, fourth, or fifth year of studies, or a recent graduate

How to apply
If you are interested in the position, kindly submit your CV, cover letter and academic transcript to recruitment@accentequity.se no later than 4th of April. We recruit on a rolling basis, so early submissions are encouraged.

For any inquiries, please reach out to Jesper Björkman at jesper.bjorkman@accentequity.se.

About Accent Equity
Accent Equity has since 1994 invested in private Nordic companies where a new partner or owner can serve as a catalyst. Our ambition is to invest in and develop the companies to be Nordic, European or Global leaders through a professional, hands-on and long-term oriented approach that results in superior and sustainable returns.

March 6, 2025 – Boston, MA – Charlesbank Capital Partners, a middle-market private investment firm, is pleased to announce the appointment of Michael Treisman as Managing Director, General Counsel and Chief Compliance Officer. Mr. Treisman has over 20 years of experience advising private fund managers and is well-known in the private equity, credit and legal communities.

For the past 10 years, Mr. Treisman has worked in-house at Bain Capital, where he was a Partner and the global General Counsel to the firm’s Special Situations, Credit, Public Equity, Insurance and Partnership Strategies businesses since 2018. During his time at Bain Capital, Mr. Treisman was integrally involved in the management and growth of these businesses.

Mr. Treisman has extensive experience negotiating and structuring complex transactions and fundraisings, overseeing litigation and regulatory matters, and handling a wide range of corporate and operational issues. Earlier in his career, he was the Chief Legal Officer and Chief Compliance Officer for Tiger Management LLC and held senior legal roles across multiple businesses at Citi Alternative Investments.

“We are delighted to welcome Michael to Charlesbank. With his wealth of experience as a private fund general counsel and deep knowledge of regulatory and compliance matters, we are confident that he will transition smoothly into this role and prove to be a great addition to our leadership team,” said Josh Klevens, Managing Director and Chief Operating Officer at Charlesbank.

Mr. Treisman received a JD from Duke University School of Law in 2000 and a BA from the University of Pennsylvania in 1994.

Naarden, The Netherlands – 03 March 2025 – Forbion is pleased to announce the appointment of Regina Salvat, PhD, as Principal in our Boston office. This strategic hire underscores our commitment to strengthening our presence in the United States and enhancing our investment capabilities in the biotech sector.

Regina joins Forbion from Sofinnova Investments, where she was instrumental in driving multiple successful private investments across the biotechnology landscape. She holds a PhD in Protein Engineering from Dartmouth College and a Bachelor’s degree in Biomedical Engineering from Cornell University. Her extensive experience and robust network will be invaluable assets as she collaborates with the Forbion Growth team, focusing on private and crossover investment opportunities.

Regina is no stranger to Forbion, having previously collaborated on successful investments in companies such as Capstan Therapeutics, Aiolos Bio, and Gyroscope Therapeutics. Her proven track record in identifying and nurturing high-impact biotech ventures aligns seamlessly with Forbion’s mission to support innovative companies that transform patient care.

Managing Partner Martien van Osch, co-founder of Forbion, emphasizes the significance of these developments, “The expansion into Boston and the addition of seasoned professionals like Regina reflect Forbion’s dedication to fostering innovation and supporting groundbreaking biotech companies. Our presence in this dynamic biotech hub enables us to better serve our portfolio and identify new investment opportunities that align with our mission to bring transformative therapies to patients.”

The establishment of our Boston office in June 2024 marked a significant milestone in Forbion’s expansion strategy. Located on Clarendon Street, this office serves as a hub for Forbion’s U.S. operations, enabling closer collaboration with portfolio companies and access to a vibrant biotech ecosystem. The Boston team to date includes Managing Partner Martien van Osch, General Partner Josh Brumm and Partner Jonathan McNeill, MD.

Forbion remains committed to building a talented team to drive our mission forward. We are confident that the expertise and leadership of our Boston team will significantly contribute to the growth and success of our portfolio companies and the broader biotech community.

For more information, please contact:

Forbion Communications
Email: laura.asbjornsen@forbion.com
Head of Communications

About Forbion
Forbion is a leading global venture capital firm with deep expertise in Europe and offices in Naarden, The Netherlands, Munich, Germany and Boston, USA. Forbion invests in innovative biotech companies, managing approximately €5 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. In addition, Forbion leverages its biotech expertise beyond human health to address ‘planetary health’ challenges through its BioEconomy fund strategy, which invests in companies developing sustainable solutions in food, agriculture, materials, and environmental technologies. Forbion’s team consists of over 30 investment professionals that have built an impressive performance track record since the late nineties with 128 investments across 11 funds. Forbion’s record of sourcing, building and guiding life sciences companies has resulted in many approved breakthrough therapies and valuable exits. Forbion typically selects impactful investments that will positively affect the health and well-being of people and the planet, as well as meet its financial return objectives. The firm is a signatory to the United Nations Principles for Responsible Investment. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.